Does the media prefer FDMT or VRDN?

In the previous week, 4D Molecular Therapeutics had 7 more articles in the media than Viridian Therapeutics. MarketBeat recorded 17 mentions for 4D Molecular Therapeutics and 10 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.04 beat 4D Molecular Therapeutics' score of 0.53 indicating that Viridian Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 4D Molecular Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viridian Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to FDMT or NKTR?

In the previous week, Nektar Therapeutics had 5 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 22 mentions for Nektar Therapeutics and 17 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.53 beat Nektar Therapeutics' score of 0.44 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 4D Molecular Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nektar Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer AMLX or FDMT?

In the previous week, Amylyx Pharmaceuticals had 25 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 42 mentions for Amylyx Pharmaceuticals and 17 mentions for 4D Molecular Therapeutics. Amylyx Pharmaceuticals' average media sentiment score of 0.71 beat 4D Molecular Therapeutics' score of 0.53 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 14 Very Positive mention(s) 7 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive 4D Molecular Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to FDMT or KLRA?

In the previous week, 4D Molecular Therapeutics had 13 more articles in the media than Kailera Therapeutics. MarketBeat recorded 17 mentions for 4D Molecular Therapeutics and 4 mentions for Kailera Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.53 beat Kailera Therapeutics' score of -0.05 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 4D Molecular Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kailera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

4D Molecular Therapeutics (FDMT) Competitors

$15.83 -0.27 (-1.68%)

As of 08/21/2026 04:00 PM Eastern

Compare

FDMT vs. VRDN, BCRX, NKTR, AMLX, and KLRA

Should you buy 4D Molecular Therapeutics stock or one of its competitors? 4D Molecular Therapeutics's main competitors and comparable companies include Viridian Therapeutics (VRDN), BioCryst Pharmaceuticals (BCRX), Nektar Therapeutics (NKTR), Amylyx Pharmaceuticals (AMLX), and Kailera Therapeutics (KLRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does 4D Molecular Therapeutics compare to Viridian Therapeutics?

4D Molecular Therapeutics (NASDAQ:FDMT) and Viridian Therapeutics (NASDAQ:VRDN) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends.

4D Molecular Therapeutics presently has a consensus price target of $29.63, suggesting a potential upside of 87.14%. Viridian Therapeutics has a consensus price target of $38.93, suggesting a potential upside of 60.27%. Given 4D Molecular Therapeutics' higher possible upside, equities analysts clearly believe 4D Molecular Therapeutics is more favorable than Viridian Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86

4D Molecular Therapeutics has a beta of 2.73, meaning that its stock price is 173% more volatile than the broader market. Comparatively, Viridian Therapeutics has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 7.9% of 4D Molecular Therapeutics shares are held by company insiders. Comparatively, 2.4% of Viridian Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

4D Molecular Therapeutics has a net margin of -194.74% compared to Viridian Therapeutics' net margin of -505.86%. 4D Molecular Therapeutics' return on equity of -41.33% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-194.74%	-41.33%	-35.90%
Viridian Therapeutics	-505.86%	-72.97%	-42.80%

In the previous week, 4D Molecular Therapeutics had 7 more articles in the media than Viridian Therapeutics. MarketBeat recorded 17 mentions for 4D Molecular Therapeutics and 10 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.04 beat 4D Molecular Therapeutics' score of 0.53 indicating that Viridian Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
4D Molecular Therapeutics	7 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viridian Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

4D Molecular Therapeutics has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$85.21M	10.26	-$140.11M	-$2.63	N/A
Viridian Therapeutics	$70.85M	38.84	-$342.60M	-$3.37	N/A

Summary

4D Molecular Therapeutics beats Viridian Therapeutics on 13 of the 17 factors compared between the two stocks.

How does 4D Molecular Therapeutics compare to BioCryst Pharmaceuticals?

4D Molecular Therapeutics (NASDAQ:FDMT) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 7.9% of 4D Molecular Therapeutics shares are held by insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

BioCryst Pharmaceuticals has a net margin of -40.90% compared to 4D Molecular Therapeutics' net margin of -194.74%. 4D Molecular Therapeutics' return on equity of -41.33% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-194.74%	-41.33%	-35.90%
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%

4D Molecular Therapeutics has a beta of 2.73, indicating that its share price is 173% more volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market.

4D Molecular Therapeutics presently has a consensus target price of $29.63, suggesting a potential upside of 87.14%. BioCryst Pharmaceuticals has a consensus target price of $20.60, suggesting a potential upside of 115.48%. Given BioCryst Pharmaceuticals' higher probable upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than 4D Molecular Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
BioCryst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67

BioCryst Pharmaceuticals has higher revenue and earnings than 4D Molecular Therapeutics. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$85.21M	10.26	-$140.11M	-$2.63	N/A
BioCryst Pharmaceuticals	$940.61M	2.60	$263.86M	-$1.50	N/A

In the previous week, 4D Molecular Therapeutics had 10 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 17 mentions for 4D Molecular Therapeutics and 7 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 0.95 beat 4D Molecular Therapeutics' score of 0.53 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
4D Molecular Therapeutics	7 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioCryst Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

4D Molecular Therapeutics beats BioCryst Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does 4D Molecular Therapeutics compare to Nektar Therapeutics?

4D Molecular Therapeutics (NASDAQ:FDMT) and Nektar Therapeutics (NASDAQ:NKTR) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

4D Molecular Therapeutics currently has a consensus price target of $29.63, indicating a potential upside of 87.14%. Nektar Therapeutics has a consensus price target of $141.50, indicating a potential upside of 91.16%. Given Nektar Therapeutics' higher probable upside, analysts clearly believe Nektar Therapeutics is more favorable than 4D Molecular Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Nektar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 7.9% of 4D Molecular Therapeutics shares are owned by company insiders. Comparatively, 2.5% of Nektar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

4D Molecular Therapeutics has a net margin of -194.74% compared to Nektar Therapeutics' net margin of -287.84%. Nektar Therapeutics' return on equity of -37.87% beat 4D Molecular Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-194.74%	-41.33%	-35.90%
Nektar Therapeutics	-287.84%	-37.87%	-25.67%

4D Molecular Therapeutics has a beta of 2.73, meaning that its share price is 173% more volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market.

4D Molecular Therapeutics has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$85.21M	10.26	-$140.11M	-$2.63	N/A
Nektar Therapeutics	$55.23M	45.75	-$164.08M	-$6.70	N/A

In the previous week, Nektar Therapeutics had 5 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 22 mentions for Nektar Therapeutics and 17 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.53 beat Nektar Therapeutics' score of 0.44 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
4D Molecular Therapeutics	7 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nektar Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

4D Molecular Therapeutics beats Nektar Therapeutics on 11 of the 17 factors compared between the two stocks.

How does 4D Molecular Therapeutics compare to Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

Amylyx Pharmaceuticals has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -194.74%. 4D Molecular Therapeutics' return on equity of -41.33% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%
4D Molecular Therapeutics	-194.74%	-41.33%	-35.90%

4D Molecular Therapeutics has lower revenue, but higher earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	49.30	-$144.74M	-$1.43	N/A
4D Molecular Therapeutics	$85.21M	10.26	-$140.11M	-$2.63	N/A

Amylyx Pharmaceuticals has a beta of -0.21, suggesting that its stock price is 121% less volatile than the broader market. Comparatively, 4D Molecular Therapeutics has a beta of 2.73, suggesting that its stock price is 173% more volatile than the broader market.

Amylyx Pharmaceuticals currently has a consensus price target of $36.25, indicating a potential downside of 6.23%. 4D Molecular Therapeutics has a consensus price target of $29.63, indicating a potential upside of 87.14%. Given 4D Molecular Therapeutics' higher probable upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Amylyx Pharmaceuticals had 25 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 42 mentions for Amylyx Pharmaceuticals and 17 mentions for 4D Molecular Therapeutics. Amylyx Pharmaceuticals' average media sentiment score of 0.71 beat 4D Molecular Therapeutics' score of 0.53 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	14 Very Positive mention(s)	7 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
4D Molecular Therapeutics	7 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are owned by insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Amylyx Pharmaceuticals beats 4D Molecular Therapeutics on 10 of the 17 factors compared between the two stocks.

How does 4D Molecular Therapeutics compare to Kailera Therapeutics?

4D Molecular Therapeutics (NASDAQ:FDMT) and Kailera Therapeutics (NASDAQ:KLRA) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 7.9% of 4D Molecular Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Kailera Therapeutics has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -194.74%. Kailera Therapeutics' return on equity of 0.00% beat 4D Molecular Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-194.74%	-41.33%	-35.90%
Kailera Therapeutics	N/A	N/A	N/A

4D Molecular Therapeutics has higher revenue and earnings than Kailera Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$85.21M	10.26	-$140.11M	-$2.63	N/A
Kailera Therapeutics	N/A	N/A	-$148.96M	-$3.65 thousand	N/A

In the previous week, 4D Molecular Therapeutics had 13 more articles in the media than Kailera Therapeutics. MarketBeat recorded 17 mentions for 4D Molecular Therapeutics and 4 mentions for Kailera Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.53 beat Kailera Therapeutics' score of -0.05 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
4D Molecular Therapeutics	7 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kailera Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

4D Molecular Therapeutics presently has a consensus target price of $29.63, suggesting a potential upside of 87.14%. Kailera Therapeutics has a consensus target price of $42.75, suggesting a potential upside of 148.98%. Given Kailera Therapeutics' higher probable upside, analysts plainly believe Kailera Therapeutics is more favorable than 4D Molecular Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Kailera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

4D Molecular Therapeutics beats Kailera Therapeutics on 9 of the 14 factors compared between the two stocks.

Get 4D Molecular Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FDMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FDMT vs. The Competition

Export

Metric	4D Molecular Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$874.51M	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-6.02	11.62	272.88	24.24
Price / Sales	10.26	1,338.17	618.96	99.81
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	2.14	16.80	13.05	6.20
Net Income	-$140.11M	-$12.50M	$3.47B	$348.59M
7 Day Performance	29.86%	3.29%	2.09%	0.08%
1 Month Performance	52.50%	8.23%	6.64%	3.88%
1 Year Performance	123.27%	55.05%	25.02%	16.98%

4D Molecular Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FDMT 4D Molecular Therapeutics	3.0677 of 5 stars	$15.83 -1.7%	$29.63 +87.1%	+123.3%	$874.51M	$85.21M	N/A	120	Analyst Revision
VRDN Viridian Therapeutics	2.7292 of 5 stars	$23.09 +4.6%	$38.93 +68.6%	+26.3%	$2.50B	$70.85M	N/A	50	News Coverage Positive News Insider Trade
BCRX BioCryst Pharmaceuticals	2.8354 of 5 stars	$9.94 +2.1%	$20.60 +107.2%	+11.7%	$2.49B	$874.84M	N/A	530
NKTR Nektar Therapeutics	2.9193 of 5 stars	$72.67 -0.5%	$150.00 +106.4%	+173.8%	$2.47B	$55.23M	N/A	220	Trending News Analyst Forecast Analyst Revision
AMLX Amylyx Pharmaceuticals	1.7939 of 5 stars	$21.43 -0.9%	$26.13 +21.9%	+315.7%	$2.41B	$87.37M	N/A	200	Trending News Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FDMT) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

4D Molecular Therapeutics (FDMT) Competitors

FDMT vs. VRDN, BCRX, NKTR, AMLX, and KLRA

How does 4D Molecular Therapeutics compare to Viridian Therapeutics?

Summary

How does 4D Molecular Therapeutics compare to BioCryst Pharmaceuticals?

Summary

How does 4D Molecular Therapeutics compare to Nektar Therapeutics?

Summary

How does 4D Molecular Therapeutics compare to Amylyx Pharmaceuticals?

Summary

How does 4D Molecular Therapeutics compare to Kailera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FDMT vs. The Competition

4D Molecular Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

4D Molecular Therapeutics (FDMT) Competitors

FDMT vs. VRDN, BCRX, NKTR, AMLX, and KLRA

How does 4D Molecular Therapeutics compare to Viridian Therapeutics?

Do analysts recommend FDMT or VRDN?

Which has more risk and volatility, FDMT or VRDN?

Do insiders & institutionals believe in FDMT or VRDN?

Is FDMT or VRDN more profitable?

Does the media prefer FDMT or VRDN?

Which has higher earnings & valuation, FDMT or VRDN?

Summary

How does 4D Molecular Therapeutics compare to BioCryst Pharmaceuticals?

Do insiders and institutionals believe in FDMT or BCRX?

Is FDMT or BCRX more profitable?

Which has more risk and volatility, FDMT or BCRX?

Do analysts rate FDMT or BCRX?

Which has stronger valuation and earnings, FDMT or BCRX?

Does the media refer more to FDMT or BCRX?

Summary

How does 4D Molecular Therapeutics compare to Nektar Therapeutics?

Do analysts recommend FDMT or NKTR?

Do insiders & institutionals have more ownership in FDMT or NKTR?

Is FDMT or NKTR more profitable?

Which has more risk and volatility, FDMT or NKTR?

Which has preferable earnings and valuation, FDMT or NKTR?

Does the media refer more to FDMT or NKTR?

Summary

How does 4D Molecular Therapeutics compare to Amylyx Pharmaceuticals?

Is AMLX or FDMT more profitable?

Which has better earnings and valuation, AMLX or FDMT?

Which has more risk & volatility, AMLX or FDMT?

Do analysts recommend AMLX or FDMT?

Does the media prefer AMLX or FDMT?

Do insiders and institutionals have more ownership in AMLX or FDMT?

Summary

How does 4D Molecular Therapeutics compare to Kailera Therapeutics?

Do institutionals and insiders hold more shares of FDMT or KLRA?

Is FDMT or KLRA more profitable?

Which has better valuation and earnings, FDMT or KLRA?

Does the media refer more to FDMT or KLRA?

Do analysts recommend FDMT or KLRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FDMT vs. The Competition

4D Molecular Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools